A heterologous MF59-adjuvanted H5N1 prepandemic influenza booster vaccine induces a robust, cross-reactive immune response in adults and the elderly - PubMed (original) (raw)

A heterologous MF59-adjuvanted H5N1 prepandemic influenza booster vaccine induces a robust, cross-reactive immune response in adults and the elderly

Elena Fragapane et al. Clin Vaccine Immunol. 2010 Nov.

Abstract

Immunogenicity and safety of a booster dose of an MF59-adjuvanted H5N1 vaccine containing 7.5 μg A/turkey/Turkey/1/2005-like (clade 2.2) H5N1 hemagglutinin, given approximately 18 months after primary vaccination with a heterologous strain, were evaluated. The booster vaccine was well tolerated and induced a robust, cross-reactive immune response.

PubMed Disclaimer

Figures

FIG. 1.

FIG. 1.

Reported incidences of local and systemic reactions for nonelderly adults (18 to 60 years of age; white bars) and elderly adults (>60 years of age; black bars).

References

    1. Atmar, R. L., W. A. Keitel, S. M. Patel, et al. 2006. Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations. Clin. Infect. Dis. 43**:**1135-1142. -PubMed
    1. Banzhoff, A., R. Gasparini, F. Laghi-Pasini, et al. 2009. Pre-pandemic influenza immunization: MF59-adjuvanted H5N1 vaccine induces immunogenic memory and heterotypic antibody response in non-elderly and elderly adults. PLoS One 4**:**e4384. -PMC -PubMed
    1. Banzhoff, A., M. Pellegrini, G. Del Giudice, E. Fragapane, N. Groth, and A. Podda, 2008. MF59-adjuvanted vaccines for seasonal and pandemic influenza prophylaxis. Influenza Other Respir. Viruses 2**:**243-249. -PMC -PubMed
    1. Committee for Proprietary Medicinal Products. 1997. Note for guidance on harmonization of requirements for influenza vaccines CPMP/BWP/214/96. European Agency for the Evaluation of Medicinal Products, London, United Kingdom.
    1. Jennings, L. C., A. S. Monto, P. K. Chan, T. D. Szucs, and K. G. Nicholson. 2008. Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans. Lancet Infect. Dis. 8**:**650-658. -PubMed

MeSH terms

Substances

LinkOut - more resources